-
Government of Canada invests in innovative businesses with support for La Ruche
-
Government of Canada invests in workforce training to support the life sciences and biomanufacturing sector
-
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
-
New VR tech gives assisted living facility residents a chance to explore world
-
FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
-
Old drug, new tricks: prostate drug could be useful in Alzheimer’s disease
-
Bridging science and AI for impact: a conversation with Re:Pair Genomics CEO Shiron Lee
-
Tecumseh approves MOU for new Alzheimer Society regional headquarters
-
CABHI and the Government of Ontario deepen partnership to develop highly qualified talent and translate research into economic and social impact
-
Avoiding 3 Things During Middle Age Is Linked to 13 More Years Without Dementia
-
Taipei's AI Healthcare Ecosystem Connects with Japan's Kansai Region as 15 Companies Showcase Taiwan-Japan Innovation Linkages
-
Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
